{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:54:17Z","timestamp":1768877657140,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ejmech.2023.115463","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T13:02:21Z","timestamp":1684155741000},"page":"115463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Optimization, and biological evaluation of 3-O-\u03b2-chacotriosyl betulinic acid amide derivatives as novel small-molecule Omicron"],"prefix":"10.1016","volume":"256","author":[{"given":"Mingjian","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinshen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongfeng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enlin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaopeng","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115463_bib1","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0140-6736(20)30673-5","article-title":"COVID-19: towards controlling of a pandemic","volume":"395","author":"Bedford","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2023.115463_bib2","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1093\/cid\/ciac625","article-title":"Association tetween AZD7442 (Tixagevimab-Cilgavimab) administration and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, hospitalization, and mortality","volume":"76","author":"Kertes","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2023.115463_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2313","article-title":"Covid-19 vaccines and variants of concern: a review","volume":"32","author":"Hadj Hassine","year":"2022","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.ejmech.2023.115463_bib4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41392-022-00996-y","article-title":"COVID-19 vaccine development: milestones, lessons and prospects","volume":"7","author":"Li","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2023.115463_bib5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","article-title":"Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants","volume":"186","author":"Wang","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.115463_bib6","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","article-title":"The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic","volume":"185","author":"Hoffmann","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.115463_bib7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41392-022-00997-x","article-title":"SARS-CoV-2 Omicron variant: recent progress and future perspectives","volume":"7","author":"Fan","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2023.115463_bib8","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion","volume":"30","author":"Xia","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2023.115463_bib9","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3390\/v14020353","article-title":"Screening of botanical drugs against SARS-CoV-2 entry reveals novel therapeutic agents to treat COVID-19","volume":"14","author":"Cao","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2023.115463_bib10","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/s41401-020-00556-6","article-title":"Identification of SARS-CoV-2 entry inhibitors among already approved drugs","volume":"42","author":"ang","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2023.115463_bib11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion","volume":"30","author":"Xia","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2023.115463_bib12","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1021\/acsmedchemlett.1c00263","article-title":"Discovery of small molecule entry inhibitors targeting the fusion peptide of SARS-CoV-2 spike protein","volume":"12","author":"Hu","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115463_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01245-22","article-title":"Sertraline is an effective SARS-CoV-2 entry inhibitor targeting the spike protein","volume":"96","author":"Chen","year":"2022","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2023.115463_bib14","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1073\/pnas.2003138117","article-title":"Cell entry mechanisms of SARS-CoV-2","volume":"117","author":"Shang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2023.115463_bib15","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41586-021-03491-6","article-title":"Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia","volume":"594","author":"Braga","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115463_bib16","article-title":"SARS-CoV-2 spike engagement of ACE2 primes S2' site cleavage and fusion initiation","volume":"119","author":"Yu","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2023.115463_bib17","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2201433119","article-title":"Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants","volume":"119","author":"Hong","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2023.115463_bib18","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/s41422-022-00746-3","article-title":"A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein","volume":"32","author":"Pang","year":"2022","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2023.115463_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo3153","article-title":"Intermediates in SARS-CoV-2 spike-mediated cell entry","volume":"8","author":"Marcink","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2023.115463_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105445","article-title":"Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides","volume":"208","author":"Zhu","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2023.115463_bib21","doi-asserted-by":"crossref","first-page":"pgac198","DOI":"10.1093\/pnasnexus\/pgac198","article-title":"Targeting an evolutionarily conserved \"E-L-L\" motif in spike protein to identify a small molecule fusion inhibitor against SARS-CoV-2","volume":"1","author":"Jana","year":"2022","journal-title":"PNAS Nexus"},{"key":"10.1016\/j.ejmech.2023.115463_bib22","article-title":"Drug repurposing of itraconazole and estradiol benzoate against COVID-19 by blocking SARS-CoV-2 spike protein-mediated membrane fusion","volume":"4","author":"Yang","year":"2021","journal-title":"Adv. Ther."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115463_bib23","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.apsb.2021.07.026","article-title":"A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases","volume":"12","author":"Zhou","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2023.115463_bib24","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41392-021-00712-2","article-title":"Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation, Signal","volume":"6","author":"Xia","year":"2021","journal-title":"Transduct. Target. Ther."},{"key":"10.1016\/j.ejmech.2023.115463_bib25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion","volume":"30","author":"Xia","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2023.115463_bib26","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41392-020-00325-1","article-title":"Salvianolic acid C potently inhibits SARS-CoV-2 infection by blocking the formation of six-helix bundle core of spike protein, Signal","volume":"5","author":"Yang","year":"2020","journal-title":"Transduct. Target. Ther."},{"key":"10.1016\/j.ejmech.2023.115463_bib27","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41586-021-03431-4","article-title":"Clofazimine broadly inhibits coronaviruses including SARS-CoV-2","volume":"593","author":"Yuan","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115463_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114295","article-title":"Design, synthesis and biological evaluations of niclosamide analogues against SARS-CoV-2","volume":"235","author":"Juang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115463_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106316","article-title":"Discovery and structural optimization of 3-O-\u03b2-chacotriosyl betulonic acid saponins as potent fusion inhibitors of Omicron virus infections","volume":"131","author":"Liu","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115463_bib30","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejmech.2013.11.024","article-title":"A \"natural\" approach: synthesis and cytoxicity of monodesmosidic glycyrrhetinic acid glycosides","volume":"72","author":"Schwarz","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115463_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112920","article-title":"Cytotoxic triterpenoide- safirinium conjugates target the endoplasmic reticulum","volume":"209","author":"Kraft","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115463_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114426","article-title":"Identification, optimization, and biological evaluation of 3-O-\u03b2-chacotriosyl ursolic acid derivatives as novel SARS-CoV-2 entry inhibitors by targeting the prefusion state of spike protein","volume":"238","author":"Li","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115463_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112048","article-title":"Synthesis and SARs of dopamine derivatives as potential inhibitors of influenza virus PAN endonuclease","volume":"189","author":"Liao","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115463_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113929","article-title":"Discovery and optimization of new 6, 7-dihydroxy-1, 2, 3, 4-tetrahydroisoquinoline derivatives as potent influenza virus PAN inhibitors","volume":"227","author":"Liu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115463_bib35","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1021\/acs.jmedchem.2c00857","article-title":"Identification of N- and C-3-modified laudanosoline derivatives as novel influenza PAN endonuclease inhibitors","volume":"66","author":"Liao","year":"2023","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423004294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423004294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:57:54Z","timestamp":1759330674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423004294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":35,"alternative-id":["S0223523423004294"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115463","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization, and biological evaluation of 3-O-\u03b2-chacotriosyl betulinic acid amide derivatives as novel small-molecule Omicron","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115463","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115463"}}